Literature DB >> 28004184

Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.

Christoph Sinning1, Francisco Ojeda1, Philipp S Wild2,3,4, Renate B Schnabel1,5, Michael Schwarzl1,5, Sevenai Ohdah1, Karl J Lackner6, Norbert Pfeiffer7, Matthias Michal3,4,8, Maria Blettner9, Thomas Munzel2,4, Tibor Kempf10, Kai C Wollert10, Kari Kuulasmaa11, Stefan Blankenberg1,5, Veikko Salomaa11, Dirk Westermann1,5, Tanja Zeller12,13.   

Abstract

BACKGROUND: Obesity is a risk factor for heart failure (HF) and identification of symptomatic, and obese HF patients are challenging, because obesity can mimic HF symptoms. We aimed to evaluate novel biomarkers for HF in obese subjects of the general population.
METHODS: Midregional proadrenomedullin (MR-proADM), growth differentiation factor-15 (GDF-15), midregional pro-atrial natriuretic peptide (MR-proANP), and NT-proBNP were measured in 5000 individuals of the population-based Gutenberg Health Study (GHS), including 1204 obese individuals (BMI ≥ 30 kg/m2) and 107 individuals with HF.
RESULTS: NT-proBNP and MR-proANP were lower in obese vs. non-obese HF individuals (p = 0.013 and p = 0.01, respectively), whereas GDF-15 was similar and MR-proADM was higher in obese vs. non-obese HF individuals. All biomarkers increased the odds ratio (OR) for prevalent HF. For NT-proBNP and MR-proANP, this increase was lower in obese vs. non-obese individuals, whereas it was comparable for MR-proADM and GDF-15. All biomarkers were associated with increased all-cause mortality (median follow-up 7.3 years, 211 events). Results were validated in 8373 individuals (n = 1734 with BMI ≥ 30 kg/m2) of the FINRISK study with a median follow-up of 13.8 years (1030 events). Using a dichotomized biomarker cutoff for HF, the best predictor for all-cause mortality in obese subjects was GDF-15 (p < 0.001).
CONCLUSION: All biomarkers were associated with HF and higher risk for all-cause mortality in the general population. In contrast to the natriuretic peptides NT-proBNP and MR-proANP, the novel biomarkers MR-proADM and GDF-15 were not lower in obese HF individuals, indicating their potential to facilitate HF diagnosis and prognosis in an increasingly obese HF population.

Entities:  

Keywords:  Growth differentiation factor-15; Heart failure; MR-proADM; NT-proBNP; Natriuretic peptides; Obesity

Mesh:

Substances:

Year:  2016        PMID: 28004184     DOI: 10.1007/s00392-016-1066-x

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  34 in total

1.  Distribution and categorization of left ventricular measurements in the general population: results from the population-based Gutenberg Heart Study.

Authors:  Philipp S Wild; Christoph R Sinning; Alexander Roth; Sandra Wilde; Renate B Schnabel; Edith Lubos; Tanja Zeller; Till Keller; Karl J Lackner; Maria Blettner; Ramachandran S Vasan; Thomas Münzel; Stefan Blankenberg
Journal:  Circ Cardiovasc Imaging       Date:  2010-07-19       Impact factor: 7.792

2.  Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study.

Authors:  Sandeep R Das; Mark H Drazner; Daniel L Dries; Gloria L Vega; Harold G Stanek; Shuaib M Abdullah; Russell M Canham; Anne K Chung; David Leonard; Frank H Wians; James A de Lemos
Journal:  Circulation       Date:  2005-10-04       Impact factor: 29.690

3.  GDF-15 in heart failure: providing insight into end-organ dysfunction and its recovery?

Authors:  Kai C Wollert; Tibor Kempf
Journal:  Eur J Heart Fail       Date:  2012-10-08       Impact factor: 15.534

4.  Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy.

Authors:  Daniel G Krauser; Donald M Lloyd-Jones; Claudia U Chae; Renee Cameron; Saif Anwaruddin; Aaron L Baggish; Annabel Chen; Roderick Tung; James L Januzzi
Journal:  Am Heart J       Date:  2005-04       Impact factor: 4.749

5.  How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study.

Authors:  Lori B Daniels; Paul Clopton; Vikas Bhalla; Padma Krishnaswamy; Richard M Nowak; James McCord; Judd E Hollander; Philippe Duc; Torbjørn Omland; Alan B Storrow; William T Abraham; Alan H B Wu; Philippe G Steg; Arne Westheim; Cathrine Wold Knudsen; Alberto Perez; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough; Alan S Maisel
Journal:  Am Heart J       Date:  2006-05       Impact factor: 4.749

6.  N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome.

Authors:  Michael H Olsen; Tine W Hansen; Marina K Christensen; Finn Gustafsson; Susanne Rasmussen; Kristian Wachtell; Knut Borch-Johnsen; Hans Ibsen; Torben Jørgensen; Per Hildebrandt
Journal:  Hypertension       Date:  2005-08-29       Impact factor: 10.190

7.  Measures of obesity and cardiovascular risk among men and women.

Authors:  Rebecca P Gelber; J Michael Gaziano; E John Orav; Joann E Manson; Julie E Buring; Tobias Kurth
Journal:  J Am Coll Cardiol       Date:  2008-08-19       Impact factor: 24.094

8.  Impact of obesity on plasma natriuretic peptide levels.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Peter W F Wilson; Ramachandran S Vasan
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

9.  Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms.

Authors:  Enrico Vizzardi; Edoardo Sciatti; Ivano Bonadei; Antonio D'Aloia; Lamia Tartière-Kesri; Jean-Michel Tartière; Alain Cohen-Solal; Marco Metra
Journal:  Clin Res Cardiol       Date:  2015-06-10       Impact factor: 5.460

10.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

View more
  6 in total

Review 1.  Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.

Authors:  Alexander E Berezin; Alexander A Berezin
Journal:  Dis Markers       Date:  2020-06-12       Impact factor: 3.434

2.  Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD).

Authors:  Robert Claus; Dominik Berliner; Udo Bavendiek; Nicolas Vodovar; Ralf Lichtinghagen; Sascha David; Margret Patecki; Jean-Marie Launay; Johann Bauersachs; Hermann Haller; Marcus Hiss; Michael S Balzer
Journal:  Clin Res Cardiol       Date:  2020-01-30       Impact factor: 5.460

3.  Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH.

Authors:  Steffen D Kriechbaum; Lillith Scherwitz; Christoph B Wiedenroth; Felix Rudolph; Jan-Sebastian Wolter; Moritz Haas; Ulrich Fischer-Rasokat; Andreas Rolf; Christian W Hamm; Eckhard Mayer; Stefan Guth; Till Keller; Stavros V Konstantinides; Mareike Lankeit; Christoph Liebetrau
Journal:  ERJ Open Res       Date:  2020-11-02

4.  Association of circulating MR-proADM with all-cause and cardiovascular mortality in the general population: Results from the KORA F4 cohort study.

Authors:  Christina Gar; Barbara Thorand; Christian Herder; Chaterina Sujana; Margit Heier; Christa Meisinger; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Michael Roden; Michael Stumvoll; Haifa Maalmi; Thomas Meitinger; Holger Then; Jochen Seissler; Cornelia Then
Journal:  PLoS One       Date:  2022-01-06       Impact factor: 3.240

5.  Integrated analyses of growth differentiation factor-15 concentration and cardiometabolic diseases in humans.

Authors:  Susanna Lemmelä; Eleanor M Wigmore; Christian Benner; Aki S Havulinna; Rachel M Y Ong; Tibor Kempf; Kai C Wollert; Stefan Blankenberg; Tanja Zeller; James E Peters; Veikko Salomaa; Maria Fritsch; Ruth March; Aarno Palotie; Mark Daly; Adam S Butterworth; Mervi Kinnunen; Dirk S Paul; Athena Matakidou
Journal:  Elife       Date:  2022-08-02       Impact factor: 8.713

6.  Early Stages of Obesity-related Heart Failure Are Associated with Natriuretic Peptide Deficiency and an Overall Lack of Neurohormonal Activation: The Copenhagen Heart Failure Risk Study.

Authors:  Freja Stoltze Gaborit; Caroline Kistorp; Thomas Kümler; Christian Hassager; Niels Tønder; Kasper Iversen; Pia R Kamstrup; Jens Faber; Lars Køber; Morten Schou
Journal:  Glob Heart       Date:  2020-03-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.